X4 Pharmaceuticals reported total revenue of $14.4 million for the first nine months of 2026, a decrease from $32.5 million in the prior year period, primarily due to lower license revenue. Net product revenue from XOLREMDI grew to $7.6 million year-to-date, while the company reduced its nine-month operating loss to $56.7 million through significant cuts in research, development, and administrative expenses.
X4 Pharmaceuticals is hosting a Virtual Investor Day on October 29, 2026, to provide updates on its strategic business plans and clinical pipeline. The presentation focuses on the commercialization of mavorixafor for primary chronic neutropenia and the progress of the ongoing 4WARD Phase 3 clinical study.
X4 Pharmaceuticals Executive Chairman Adam R. Craig Buys $11.9K of Stock
Adam R. Craig, Executive Chairman, bought 4,600 shares of X4 Pharmaceuticals, Inc at $2.58 a share, worth $11.9K in total on Oct 16, 2026. Shares held after the trade: 333,251 (+1.4%).